semaglutide type 1 diabetes automated insulin delivery randomized trial 2025 A, design. was self-injected once weekly with the Late breaking at #EASD2024: In

Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents

The fifth factor is education

A pilot randomized controlled trial found that exenatide, another GLP-1 receptor agonist, when used as an adjunct to nicotine patches, facilitated smoking cessation and reduced post-cessation weight gain

These effects on the gastrointestinal system are mediated through GLP-1 receptors located throughout the gut